H

Hospital Universitario Reina Sofia | Clinical Research Unit

Research site
(Unclaimed)
Location
Edificio IMIBIC, Avda. Menendez Pidal s/n, Cordoba, Andalucia, Spain

Site insights

Top conditions

Top treatments

Upadacitinib
Atezolizumab
ABT-494
Azacitidine
Bococizumab
Carboplatin
Pitavastatin
Trastuzumab
Paclitaxel
Metronidazole

Parent organization

This site is a part of Hospital Universitario Reina Sofia

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

55 of 136 total trials

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Placebo
Drug: Ritlecitinib

This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.

Active, not recruiting
Age Related Macular Degeneration
Drug: HLX04-O
Drug: ranibizumab

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulati...

Enrolling
Colorectal Cancer Stage III
Colorectal Cancer Stage II
Drug: RO7198457 intravenous (IV)
Other: Observational group (no intervention)

The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus plac...

Active, not recruiting
Psoriatic Arthritis
Drug: Placebo
Drug: Upadacitinib

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresect...

Active, not recruiting
Esophageal Squamous Cell Carcinoma
Drug: Atezolizumab
Drug: Atezolizumab Matching Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lun...

Begins enrollment this month
Small Cell Lung Cancer
Drug: Topotecan
Drug: Lurbinectedin

The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fract...

Enrolling
Heart Failure With Preserved Ejection Fraction
Heart Failure
Drug: LY3540378
Drug: Placebo

The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts abou...

Active, not recruiting
Lipoprotein Disorder
Drug: LY3819469
Drug: Placebo

Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of th...

Enrolling
Crohn's Disease
Drug: Mirikizumab

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: CC-486
Drug: Venetoclax

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiov...

Enrolling
Obesity
Cardiovascular Diseases
Drug: Placebo
Drug: Retatrutide

The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight a...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Retatrutide
Locations recently updated

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Enrolling
Carcinoma, Non-Small-Cell Lung
Drug: Placebo
Drug: Selpercatinib

This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specifi...

Enrolling
HER2-positive Breast Cancer
Drug: T-DM1
Drug: placebo

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive...

Enrolling
Colorectal Neoplasms
Drug: oxaliplatin
Drug: cetuximab

This multicenter, open-label, single-arm trial will evaluate the anti-tumor activity of ZW25 (zanidatamab) monotherapy in subjects with human epiderm...

Active, not recruiting
HER2-amplified Biliary Tract Cancers
Drug: ZW25 (Zanidatamab)
Locations recently updated

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo

Trial sponsors

Pfizer logo
AbbVie logo
Amgen logo
Biogen logo
Lilly logo
Roche logo
Celgene logo
Gilead Sciences logo
Kowa logo
Seagen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems